Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial by M. J. Kooy et al.
ORIGINAL RESEARCH ARTICLE
published: 29 May 2013
doi: 10.3389/fphar.2013.00069
Does the use of an electronic reminder device with or
without counseling improve adherence to lipid-lowering
treatment? The results of a randomized controlled trial
M. J. Kooy*, B. L. G. van Wijk , E. R. Heerdink , A. de Boer and M. L. Bouvy
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
Edited by:
Bernard Vrijens, AARDEX Group,
Belgium
Reviewed by:
Jiguang Wang, Shanghai Jiaotong
University School of Medicine, China
Gail Hughes, University of Western
Cape South African Herbal Science
and Medicine Institute, South Africa
*Correspondence:
M. J. Kooy, Division of
Pharmacoepidemiology and Clinical
Pharmacology, Utrecht Institute for
Pharmaceutical Sciences, Utrecht
University, PO Box 80082, 3508 TB
Utrecht, David de Wied Building,
Universiteitsweg 99, 3584 CG,
Utrecht, Netherlands
e-mail: m.j.kooij@uu.nl
Background: Lipid-lowering treatment with statins has proven to be effective in reducing
cardiovascular events and mortality. In daily practice, however, adherence to medication is
often low and this compromises the therapeutic effect. The aim of this study was to assess
the effectiveness of an electronic reminder device (ERD) with or without counseling to
improve refill adherence and persistence for statin treatment in non-adherent patients.
Methods: A multicenter, community pharmacy-based, randomized controlled trial was
conducted in 24 pharmacies in the Netherlands among patients with pre-baseline refill
adherence rates between 50 and 80%. Eligible patients aged 65 years or older were
randomly assigned to 1 of 3 groups: (1) counseling with an ERD (n = 134), (2) ERD with
a written instruction (n = 131), and a (3) control group that received the usual treatment
(n = 134).
Main outcome measure: refill adherence to statin treatment for a 360-day period after
inclusion (PDC360). Patients with a refill rate ≥80% were considered adherent. The effect
among subgroups was also assessed.
Results: There were no relevant differences at baseline. In the counseling with ERD group
54 of 130 eligible patients received the counseling with ERD. In the ERD group, 117 of 123
eligible patients received the ERD. The proportions of adherent patients in the counseling
with ERD-group (69.2%) and in the ERD group (72.4%) were not higher than in the control
group (64.8%). Among women using statins for secondary prevention, more patients were
adherent in the ERD group (86.1%) than in the control group (52.6%) (p < 0.005). In men
using statins for secondary prevention the ERD was found to have no effect.
Conclusion: In this randomized controlled trial, no statistically significant improvement
of refill adherence was found if an ERD was used with or without counseling. However,
in a subgroup of women using statins for secondary prevention the ERD did improve
adherence significantly.
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INTRODUCTION
Statins are effective in reducing cardiovascular events and mor-
tality (West of Scotland Study Group, 1997). Despite this benefi-
cial effect, adherence to lipid-lowering treatment is substantially
worse in daily practice than in the controlled setting of ran-
domized controlled trials (Jackevicius et al., 2002; Eussen et al.,
2010). Non-adherence to statins reduces the beneficial effect and
increases the risks of cardiovascular events (Simpson andMendys,
2010).
Urquhart and Vrijens (2005) and more recently Vrijens et al.
(2012) have argued that three phases of chronic drug treatment
can be identified: acceptance of the treatment plan, execution
of the drug regimen and eventually complete discontinuation
(non-persistence) of treatment. Non-adherence can take place in
these three different stages (Vrijens et al., 2012). In this study we
focused on patients who are non-adherent in the execution phase
and defined this as “the extent to which a patient acts in accor-
dance with the prescribed interval and dose of a dosing regimen”
(Cramer et al., 2008).
Numerous attempts have been made to design interventions
to improve medication adherence for patients with chronic dis-
eases, with variable rates of success (Haynes et al., 2002, 2008;
McDonald et al., 2002; Eussen et al., 2010; Schedlbauer et al.,
2010). Almost all effective interventions were complex, incor-
porating combinations of more convenient care, information,
reminders, self-monitoring, reinforcement, counseling, family
therapy, and other forms of additional supervision or attention
by a healthcare provider (Haynes et al., 2008; Schedlbauer et al.,
2010). Johnson et al. (2006) examined the application of the
full “stages of change model” to increase patients’ taking adher-
ence to lipid-lowering treatment and patients who were treated
according to this model were more likely to be adherent at 12
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and at 18 months after intervention. This model is based on five
different stages of change: the pre-contemplation stage, contem-
plation stage, preparation stage, action stage and maintenance
stage (Prochaska et al., 1992). However, an intervention as simple
as a medication reminder has also been demonstrated to increase
adherence to antihypertensive drugs by about 6–8% (Da Costa
et al., 2005; Christensen et al., 2010) and lipid-lowering treat-
ment by 6.5–12% (Vrijens et al., 2006). A medication reminder
aims to minimize forgetfulness, which is a common reason for
non-adherence (Stone, 2001).
Studies based on pharmacy records suggest that these refill
data can be used to identify non-adherent patients (Yang et al.,
2003; Chapman et al., 2005; Perreault et al., 2005). Community
pharmacists could play an important role in improving adher-
ence (Eussen et al., 2010; Morgado et al., 2011; Taitel et al.,
2012). We therefore used refill data to select non-adherent statins
users and we designed a pharmacy-based intervention. There are
at least two reasons why adherence-improving interventions are
not successful: (1) patients who volunteer to participate in the
study were already adherent at baseline (Van Wijk et al., 2005;
Eussen et al., 2010) and (2) participation in the study can also
increase adherence in the control group [the Hawthorne effect
(Morris and Lamb, 1989)], thereby decreasing the study’s power
to detect a significant effect of the intervention. In this study we
used a framework that minimizes these two limitations. Firstly,
only non-adherent patients were included. Secondly, adherence
was assessed objectively with refill data. Finally patients were not
aware of study participation, thereby minimizing the Hawthorne
effect. The object of this study was to assess the effectiveness of
an electronic reminder device (ERD) with or without counseling
to improve refill adherence and persistence for statin treatment in
non-adherent patients.
METHODS
STUDY-DESIGN
A multicenter, community pharmacy-based, randomized con-
trolled trial (Figure 1).
PARTICIPANTS
Patients were selected in 24 community pharmacies in differ-
ent areas of the Netherlands. We included patients who had
started statins at least one year prior to inclusion and were
FIGURE 1 | Trial profile.
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non-adherent in the year prior to inclusion (refill rate between
50 and 80%). We excluded patients who were not personally
responsible for their medication intake or who received their
medication in a dosing aid, patients with a life expectancy of
less than 6 months and patients younger than 65 years. Life
expectancy is difficult to assess but this assessment was based
on personal knowledge about the patient and the prescription of
drugs used in the palliative phase. Patients who had switched to a
different statin in the 540 days before the inclusion date were also
excluded.
General practitioners received general information about the
study but were not involved in the recruitment or selection.
Patients were not asked to consent to study participation.
Patients were recruited between January 2008 and March 2008.
The Medical Ethics Review Committee (METC) of the University
Medical Centre Utrecht considered our research proposal in its
meeting dated 21 August 2007 and concluded that the Dutch
Medical Research Involving Human Subjects Act (WMO) was not
applicable (approval number 07-226) and therefore the METC’s
approval of the study was not needed. No extra data had to be
collected and there was no extra burden for the patients in the
usual care group. Patients in the intervention groups could refuse
the intervention. The trial was registered at www.clinicaltrials.gov
under the identifier NCT00493337.
Pharmacists were informed about the study and received
instructions about the randomization and intervention.
DEFINITION OF NON-ADHERENCE FOR SELECTING PATIENTS
Patients were selected based on refill data and were presented to
the pharmacist when they met the following criteria: (1) received
a prescription for a statin in the preceding month, (2) received a
prescription for the same statin between 12 and 18 months prior
to that prescription and (3) had a refill adherence between 50
and 80% of the 365 days prior to the last statin prescription cov-
ered by the same statin (see below). For patients with more than
60 consecutive days without coverage, (4) an additional refill of
a non-statin prescription was required to exclude the possibility
that the patient had moved to another pharmacy. Refill adher-
ence was assessed by calculating the proportion of the 365 days
covered before selection by using the dispensing date and the
theoretical duration of a prescription. The latter is assessed by
dividing the number tablets dispensed by the number of tablets
used daily, both available from the pharmacy computer system. In
the Netherlands 95% of patients collect their prescription drugs in
the same community pharmacy (Buurma et al., 2008).
Patients were identified by an automated search-protocol
developed by the “Stichting Farmaceutische Kengetallen” (SFK).
The SFK collects dispensing data from more than 90% of Dutch
community pharmacies. The results of the selection were pre-
sented to the pharmacist on a secure website. The pharmacists
were asked to assess if each patient was eligible. After selec-
tion by the pharmacist, patients were randomized in to 1 of the
3 intervention groups.
The 80% cut-off value is the most frequently used value for
non-adherence although its clinical relevance depends on the par-
ticular medication under study (Andrade et al., 2006). Karve et al.
(2009) found that among patients treated for hyperlipidemia,
a cut-off value of 81% was clinically relevant with regard to
diseased-related hospitalization. Patients with an adherence of
less than 50% were excluded to increase the likelihood that
patients were suboptimal users rather than complete discontin-
uers who restarted treatment.
RANDOMIZATION
Patients were randomized into one of three groups: the
Counseling with ERD group, the ERD group (with written
instruction) or the control group (usual care) in a 1:1:1 ratio using
a computer generated random number sequence. Patients were
randomized in blocks based on baseline medication adherence
(above or below 65%) and age [above or below 75 using the min-
imization method with equal weights assigned to both categories
(Scott et al., 2002; Heritier et al., 2005)].
INTERVENTION
Counseling with ERD group (1)
The pharmacist sent patients a written invitation and a followup
phone call was made 14 days after the written invitation (see
Appendix 1). The intervention consisted of two elements: the first
and most important element was the application of the stages of
change model in non-adherence counseling. The second element
was the ERD.
The 10-min counseling session by the pharmacist consisted of
five phases. The patient received feedback on their previous drug
dispensing data (1). Patients were asked if they were aware that
they were non-adherent and reasons for non-adherence were dis-
cussed (2). Patients were informed about the benefits of statin use
(3), received an ERD to help them with medication taking (4)
and were informed that after one year they would be invited for
a follow-up visit (5). The ERD (Compliance Card®, Figure 2) is
a medication reminder device that starts beeping every day at the
same time until the patient switches it off. Patients can adjust the
time.
ERD group (2)
Patients received the ERD by mail with a written instruction
about the use of the device (see Appendix 2).
Control group (3)
Patients in the control group received usual care. In the
Netherlands usual care entails: at the start of therapy, patients
receive written and spoken information about the therapy and
medication. After about 2 weeks, the patient should return for the
first refill. The patient is then asked about his or her experience,
concerns and need for information. Patients who use a statin for
more than a year do not receive counseling on a regular basis.
OUTCOMES
The pre-specified primary outcome was refill adherence to statins
based on pharmacy dispensing records. Refill adherence was
assessed by calculating the proportion of days covered of the 360
days following the index date by dividing the total days’ supply by
the number of days of study participation [PDC360 (Hess et al.,
2006)]. The index date is the date of the first prescription for a
statin after selection by SFK. The total days supplied was calcu-
lated as the sum of days dispensed within the study period. If a
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FIGURE 2 | ERD, Compliance Card®. This credit-card size ERD needs to
be activated after the first dose and gives a signal after every 24-h interval
following its activation. It actively needs to be turned off. An instruction for
the first use is printed on the card.
supply exceeded the end of the study participation, this supply
was corrected for exceeding the end of the period. The number
of days of study participation was defined as the number of days
between the index date and the index date + 360 or the last refill
date, whichever came first. For assessing the last refill date, all
refills for any drug were included. We analysed refill adherence
both as a continuous measure and as a dichotomous measure, the
latter with a threshold of 80%: patients with a PDC360 < 80%
were defined as non-adherent and patients with a PDC360≥ 80%
were defined as adherent.
The secondary outcome was the occurrence of complete dis-
continuation, defined as more than 182 consecutive days (50%)
of the 1-year observation period uncovered.
POWER CALCULATION
With a type one error (α) for a two-sided test of 0.05 and a
probability of correctly rejecting the false null hypothesis of 0.80
(1 − β) 69 patients were needed in each of the 3 arms to demon-
strate an improvement in the proportion of adherent patients
from 65 to 80% (Campbell et al., 1995). Assuming a dropout
rate of 25% (Van Wijk et al., 2005), at least 269 patients were
required. Each community pharmacist was asked to recruit at
least 15 non-adherent patients, 5 patients in each group.
HANDLING AND STORAGE OF DATA AND DOCUMENTS
All patient data were provided to the SFK by the participat-
ing pharmacies according to a pre-existing procedure to pro-
tect the study subjects’ privacy. The SFK provided the data
to the researchers at Utrecht University. All data with regard
to the patients’ identity were anonymized by the participating
pharmacies.
INTENTION TO TREAT vs. PER PROTOCOL
In daily practice, a healthcare provider can decide not to follow
treatment guidelines or a study protocol. In this study, a phar-
macist may have had good reasons not to invite a patient after
randomization. Examples are no telephone number being known
to the pharmacist or the patient having experienced a major life
event like the death of a partner. In the counseling/ERD group,
it was to be expected that a proportion of the patients would not
be willing to visit the pharmacy for counseling. Since this could
introduce a bias, we performed a per protocol (PP) analysis as
well as an intention to treat (ITT) analysis. In the PP analysis, we
only included the patients who received the intervention. In the
ITT analysis, we included all randomized patients, even when a
pharmacist decided for a specific patient not to follow the study
protocol or when a patient was not willing to visit the pharmacy
for counseling.
STATISTICAL ANALYSIS
The primary analysis was based on the ITT principle. Patient
characteristics between groups were compared using Student’s
t-test or χ2-test. As the PDC360 was not normally distributed, we
analysed the PDC360 between groups using the non-parametric
Mann–Whitney U test (SPSS for Windows version 20.0). We used
logistic multilevel analysis to study the effect on the dichoto-
mous primary outcome (MLWIN for Windows version 2.22).
The included levels were patient, GP and pharmacist. The
secondary outcome of complete discontinuation was assessed
using Cox proportional hazards. We considered a p-value of
less than 0.05 to be statistically significant. In a second anal-
ysis, the following baseline values were considered as possible
confounders and effect modifiers: age, gender, refill rate in 12
months prior inclusion, Chronic Disease Score (CDS), use of
beta-blocking agents (BBA) or calcium channel blockers (CCB)
and use of statin for secondary prevention. The CDS uses drugs
dispensed as surrogate markers for chronic illness (Von Korff
et al., 1992). Secondary prevention was defined as either con-
comitant use of one or more platelet aggregation inhibitors (PAIs,
ATC code B01AC) and/or oral antidiabetic drugs (OAD, ATC
code A10B). Effect modification was defined as a significant inter-
action (p < 0.10) between group allocation and the variable in
question.
RESULTS
PATIENT ENROLMENT AND BASELINE
A total of 399 patients considered eligible by the pharmacists
were randomly assigned to one of the two intervention groups
or the control group (Figure 1). Two patients were excluded
because they did not fill any prescription after the selection date.
A total of 16 patients were excluded because they started receiving
medication weekly after the index date.
Patient characteristics and use of medication at baseline are
presented in Table 1. Due to missing refill data before inclusion,
it was impossible to compare the use of medication of 8 patients
in the counseling/ERD group and 2 in the control group. Patient
characteristics were similar but differences were found for the use
of medication. More patients in the ERD group used BBAs than
in the control group and fewer patients in the counseling/ERD
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Table 1 | Baseline characteristics of study population.
Characteristic Counseling with ERD (n = 130) ERD only (n = 123) Control group (n = 128) Overall (n = 381)
Age, mean [SD], years 73.3 [6.6] 73.2 [5.8] 73.9 [6.5] 76.5 [6.3]
Male, n (%) 61 (46.9) 53 (43.1) 54 (42.2) 168 (44.1)
Co-medication, n (%) (n = 122)* (n = 123)* (n = 126)* (n = 371)*
Oral antidiabetics (OAD) 26 (21.3) 26 (21.1) 32 (25.4) 84 (22.6)
Insulin without OAD 4 (4.2) 5 (5.2) 5 (5.3) 14 (4.9)
Thiazide diuretics 31 (25.4) 36 (29.3) 31 (24.6) 98 (26.4)
β blocking agents (BBA) 34 (35.2) 62 (50.4) 44 (34.9) 149 (40.2)
Calcium channel blockers (CCB) 11 (9.0) 25 (20.3) 27 (21.4) 63 (17.0)
Nitrates (sublingual) 10 (8.2) 19 (15.4) 12 (9.5) 41 (11.1)
Nitrates (oral, transdermal) 6 (4.9) 11 (8.9) 9 (7.1) 26 (7.0)
Antithrombotics 65 (53.3) 65 (52.8) 65 (51.6) 195 (52.6)
ACE inhibitors 31 (25.4) 32 (26.0) 41 (32.5) 104 (28.0)
Angiotensin II receptor blockers 22 (18.0) 28 (22.8) 25 (19.8) 75 (20.2)
Platelet aggregation inhibitor (PAI) 56 (45.9) 55 (44.7) 56 (44.4) 167 (45.0)
STATIN, n (%)
Simvastatin 68 (55.7) 72 (58.5) 78 (61.9) 218 (58.8)
Pravastatin 9 (7.4) 10 (8.1) 7 (5.6) 26 (7.0)
Atorvastatin 26 (21.3) 28 (22.8) 29 (23.0) 83 (22.4)
Rosuvastatin 12 (9.8) 9 (7.3) 10 (7.9) 31 (8.4)
Fluvastatin 6 (4.9) 4 (3.3) – 10 (2.7)
Simvastatin/ezetimb 1 (0.8) – 2 (1.6) 3 (0.8)
Chronic Disease Score, mean [SD] 5.0 [2.4] 5.6 [3.1] 5.4 [2.8] 5.4 [2.8]
REFILL RATE IN YEAR PRIOR TO INCLUSION
50–66%, n (%) 43 (35.2) 48 (39.0) 45 (35.7) 136 (36.7)
67–76%, n (%) 38 (31.1) 34 (27.6) 42 (33.3) 114 (30.7)
77–80%, n (%) 41 (33.6) 41 (33.3) 39 (31.0) 121 (32.6)
Note: *Missing refill data prior inclusion of eight patients in counseling/ERD group, 0 in the ERD group and 2 in control group.
group used CCBs than in the control group. The CDS within
the three groups was comparable. There were no statistically
significant differences in refill adherence before the index date
(Mann–Whitney U test).
Baseline characteristics were also compared based on PP anal-
ysis, but this did not substantially change our findings (data not
shown).
EXECUTION OF THE INTERVENTIONS
Of the 134 eligible patients randomized to the counseling/ERD
group, 4 patients became ineligible because they received their
medication in week boxes, 116 patients were invited for counsel-
ing, and 14 patients were not invited for counseling (see Figure 3).
Of the 14 patients not invited: 2 pharmacists did not register an
invitation for any patient for counseling (n = 6), 1 pharmacist
registered an invitation for 6 patients, and 1 pharmacist excluded
2 patients after randomization. Six pharmacists did not call any
patient after the invitation by letter (n = 32). Sixteen pharmacists
invited 51 out of 116 patients by phone as well and 32 (63%) of
these patients actually received the counseling. Of the 65 patients
who were not invited by phone as well, 22 (34%) patients received
the counseling with ERD. In total 54 of the 116 invited patients
(47%) eventually received counseling and the ERD.
Out of the 123 eligible patients in the ERD group 117 (95%)
actually received the ERD. Two pharmacists did not send any
patient the ERD (n = 6), but these pharmacists did invite patients
for the counseling with ERD intervention.
PRIMARY OUTCOME: REFILL ADHERENCE
The median PDC360 (25–75th percentile) was 90.0%
(76.75–98.25) in the counseling/ERD group, 91.0% (76.00–99.00)
in the ERD group and 87.5% (75.00–99.00) in the control group
(ITT analysis). No statistically significant differences in the
median refill adherence were assessed (Mann–Whitney U test).
Using a cut-off of 80% (PDC360) 69.2% of the patients in the
counseling/ERD group were adherent compared to 72.4% in
ERD group and 64.8% in the control group (Table 2). These
differences were not significant. Since the proportions are high,
the presented odds ratios overestimate the relative risk and
should therefore not be interpreted as such (Davies et al., 1998).
A PP analysis revealed that 70.4% of the 54 patients in the
counseling/ERD group were adherent and 72.6% of the 117
patients in the ERD group (Table 2). In a second analysis we
assessed the effect of the intervention in different subgroups
shown in Table 2. The use of OAD and/or PAIs was a significant
effect modifier (p < 0.1). In patients not using OAD and/or PAIs
there was no significant difference between the ERD group and
the control group. Gender was only a significant effect modifier
(p < 0.1) in the group of patients using OAD and/or PAIs. In the
ERD group more women using OAD and/or PAIs were adherent
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FIGURE 3 | Information about inclusion of patients in ERD/counseling group.
Table 2 | Results of multilevel analyses of the effectiveness of the interventions on proportion of adherent patients (PDC360 > 80%).
Study population No. of subjects No. of adherent
subjects (%)
Crude model Adjusted model*
OR [95% CI] p OR (95% CI) p
INTERVENTION GROUP
Overall, intention to treat
Control group 128 83 (64.8) Ref. NA Ref. NA
Counseling with ERD 130 90 (69.2) 1.22 [0.72–2.06] 0.45 1.18 [0.69–2.01] 0.55
ERD only 123 89 (72.4) 1.33 [0.76–2.32] 0.55 1.49 [0.83–2.69] 0.18
Overall, per protocol
Control group 128 83 (64.8) Ref. NA Ref. NA
Counseling with ERD 54 38 (70.4) 1.29 [0.65–2.56] 0.47 1.25 [0.62–2.52] 0.54
ERD only 117 85 (72.6) 1.35 [0.77–2.36] 0.30 1.49 [0.83–2.68] 0.18
SUBGROUP ANALYSIS (BASED ON INTENTION TO TREAT ANALYSIS)
Primary prevention
Control group 52 37 (71.2) Ref. NA Ref. NA
ERD only 51 32 (62.7) 0.68 [0.29–1.57] 0.36 0.60 [0.24–1.48] 0.26
Secondary prevention, women
Control group 38 20 (52.6) Ref. NA Ref. NA
ERD only 36 31 (86.1) 5.58 [1.79–17.4] 0.003 8.26 [2.20–31.0] 0.002
Secondary prevention, men
Control group 38 26 (68.4) Ref. NA Ref. NA
ERD only 36 26 (72.2) 1.29 [0.46–3.67] 0.63 1.22 [0.36–4.11] 0.75
Presented odds ratios are the ratios of proportion of adherent patients in intervention group vs. proportion in control group. When OR > 1: the odds of being
adherent in the intervention group are higher than the odds in the control group.
Note: OR, odds ratio; CI, confidence interval; ERD, electronic reminder device.
*Adjusted model is corrected for refill adherence in 12 months before index date and use of beta-blocking agents (BBA) or calcium channel blocker (CCB).
Significant associations (p < 0.05) are printed bold.
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(86.1%) compared to the control group (52.6%). This difference
is statistically significant (p < 0.005). No effect of the ERD was
found for men using OAD and/or PAIs.
SECONDARY OUTCOME: DISCONTINUATION
In the counseling/ERD group 6.2% (8) of the patients discontin-
ued treatment with statins, compared to 5.7% (11) in the ERD
group and 9.4% (12) in the control group. The adjusted haz-
ard ratio for the counseling/ERD group vs. control group was
0.67 [95% CI 0.27–1.6] and for the ERD group 0.65 [0.25–1.7]
(Table 3).
The influence of our pre-specified threshold for optimal refill
adherence was assessed in a sensitivity analysis and no influence
on our primary conclusion was found (Table 4).
DISCUSSION
MAIN FINDINGS
In this effectiveness study we compared two interventions, (1)
counseling with an ERD and (2) only an ERD, with usual care
(control) and studied the effects on refill adherence and persis-
tence. In the ITT analysis we found a small improvement in refill
adherence in the overall population in both intervention groups,
but this was not statistically significant. After stratification the
effect of the ERD was particularly strong in female patients using
statins for secondary prevention but not in men. Although this
might be a chance finding, we believe there is an explanation for
this result. Differences in adherence between groups of patients
have been found (Jackevicius et al., 2002; Ye et al., 2007; Mann
et al., 2010), Some recent studies show that women with coronary
heart disease (Hammond et al., 2012) or MI (Carey et al., 2012;
Kirchmayer et al., 2012), are less adherent to statins than men.
However another study showed no difference between men and
women after MI (Choudhry et al., 2008). Diabetes is an indication
to prescribe statins for secondary prevention. Also in this group,
women are less adherent than men (Yang et al., 2009) Gender
differences exist in clinical management (Crilly et al., 2007; Fu
et al., 2011). As far as we know, these gender differences in clinical
management have not been studied in the Netherlands, but this
might explain the lower adherence in women and consequently
the larger effect of the intervention in women using statins for
secondary prevention (Yang et al., 2003; Chapman et al., 2005;
Perreault et al., 2005). In the control group we also found that
women using statins for secondary prevention were less adher-
ent (52.6%) than men (68.4%). So this might partly explain the
positive effect in women.
The effects of reminder devices on refill adherence have been
studied in populations, including patients with hypertension
(Christensen et al., 2010) and patients using statins (Vrijens
et al., 2006). Among patients with hypertension, use of an ERD
improved adherence to an antihypertensive drug during a mea-
surement period of 6 months. After 6 months the device had
to be returned to compile the electronic monitoring data. There
was a large dropout due to patients being unwilling to use the
device, patients not returning the device or patients not providing
self-reported adherence. This is different from our study where
patients did not have to return the device or complete a question-
naire. In the study by Vrijens, the intervention was more complex
and labor intensive than our intervention in the counseling/ERD
Table 3 | The effectiveness of the interventions on proportion of patients that discontinued therapy over time assessed using Cox proportional
hazards.
No. of subjects No. of discontinued
subjects (%)
Crude model Adjusted model*
HR [95% CI] p HR [95% CI] p
GROUP
Control group 128 12 (9.4) Ref. NA Ref. NA
Counseling with ERD 130 8 (6.2) 0.64 [0.26–1.6] 0.64 0.67 [0.27–1.6] 0.37
ERD only 123 7 (5.7) 0.60 [0.24–1.5] 0.29 0.65 [0.25–1.7] 0.37
Note: *Adjusted model is corrected for age at inclusion.
Table 4 | Result of sensitivity analysis: number and percentage of adherent patients when different thresholds were used for the definition of
“adherent.”
Threshold ERD with counseling (n = 130) ERD only (n = 123) Control group (n = 128)
n (%) OR [95% CI] n (%) OR [95% CI] n (%)
PDC ≥ 75% 101 (77.7) 0.96 [0.52–1.77] 98 (79.7) 1.02 [0.92–1.13] 100 (78.1)
PDC ≥ 80% 90 (69.2) 1.18 [0.69–2.01] 89 (72.4) 1.49 [0.83–2.69] 83 (64.8)
PDC ≥ 85% 76 (58.5) 1.16 [0.68–1.98] 76 (61.8) 1.48 [0.84–2.59] 70 (54.7)
PDC ≥ 90% 66 (50.8) 1.26 [0.75–2.13] 66 (53.7) 1.60 [0.94–2.73] 66 (44.5)
PDC ≥ 95% 49 (37.7) 1.12 [0.67–1.90] 51 (41.5) 1.09 [0.96–1.23] 51 (34.4)
Analysis based on intention to treat analysis.
Note: n, number of adherent subjects with the specified threshold. Based on multilevel analysis and corrected for refill adherence in 12 months before index date
and use of beta-blocking agents (BBA) or calcium channel blocker (CCB).
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group: at each follow-up visit the data of the electronically com-
piled dosing history were analysed together with the patient and
the study also made use of a Medication Electronic Monitoring
System. Their study found an improved adherence mainly by
improving persistence. In our study we found no effect of the
ERD on persistence (Table 3). Another difference between the
two mentioned studies and our study is that we used refill data
and not electronic monitoring data.
STRENGTHS OF THE STUDY
Although the interventions showed no significant improvement
in adherence in the overall study population, we showed that
a very simple intervention of sending an ERD to non-adherent
statin users can significantly improve medication refill adher-
ence in women using statins for secondary prevention. Our
study confirms the conclusion of Schedlbauer et al. (2010) that
reminding patients appears to be themost promising intervention
for improving adherence to statins. Many successful adherence-
improving interventions are time consuming and labor intensive
(Kripalani et al., 2007) and this hampers implementation in daily
practice. Simple interventions that are easy to implement in daily
practice for both the patient and healthcare professional offer the
most promise for improving adherence (van Dulmen et al., 2008).
But the challenge is to determine for which group of patients a
simple intervention is effective and which group of patients need
more tailored care. An example is the studied intervention with
the ERD. This was easy to implement in daily practice and did
not require much more than sending an instruction to the phar-
macies and providing the pharmacies with the devices, letters for
the patients and tools to select patients. So the ERD intervention
was easier to implement in daily practice than counseling.
LIMITATIONS OF THE STUDY
Our study has some limitations. Firstly, some pharmacists did not
follow the study protocol: they did not invite any patient for the
counseling and they did not send the ERD with instructions. It
would appear that some pharmacies did not follow the protocol
completely, as they did not register an invitation for counsel-
ing, excluded after randomization or did not sent the ERD. Also
some pharmacists did not invite the patient by telephone. For
an individual patient there might be a good reason not to follow
the protocol, for example, if the patient has recently experienced
a life event and adherence is therefore not the most important
issue at that moment in time. In the ITT analysis this diluted
the effect of the intervention since all presented patients were
included in the analysis. Only 54 of the 116 invited patients actu-
ally received the counseling. One important reason for this is that
65 patients did not receive a follow-up phone call from the phar-
macist. Apparently, an invitation letter alone is not enough to
motivate patients to visit the pharmacy. In the PP analysis we
only included patients who eventually received the counseling
or ERD. However, we believe that the effect of a selection bias
is small, as pharmacists did not selectively exclude patients after
randomization: they invited all or none. More attention should
have been given to the implementation of the intervention with
counseling. Secondly, the number of included patients is not quite
high enough and so there might have been too little power to
demonstrate a statically significant effect. Thirdly, some patients
might have been selected as non-adherent, whereas in practice
they were more than 80% adherent, for example when they were
hospitalized. However, this is likely to be non-differentially dis-
tributed among our trials arms and so would only have diluted the
effect of the intervention. Fourthly, in both intervention groups
we do not know if the patients who received the ERD with the
instruction actually used the device and neither do we know the
patients’ opinion. Future studies should investigate this in more
detail. Finally, we used a multilevel logistic regression analysis
that results in an odds ratio as an effect size. But since the pro-
portions of adherent patients are relatively high, the odds ratio
will overestimate the effect size when it is interpreted as a relative
risk (Davies et al., 1998). So although we can make a statement as
to whether there is an effect of the intervention, it is difficult to
determine the actual size of the effect.
IMPLICATIONS FOR PRACTICE AND RESEARCH
The results of this study suggest that the use of a simple ERD
can improve refill adherence in specific subgroups of patients but
not in the overall population. This justifies future studies aimed
at more accurately quantifying the effect in different groups of
patients. When an intervention for ERD use is designed we advise
focusing on persistent, but non-adherent patients. Some of the
patients in our study were not motivated to visit the pharmacy
for counseling. This group requires attention and other types of
counseling such as telephone counseling or home visits might be
more appropriate for them.
CONCLUSIONS
In this randomized controlled trial, we found no statistically
significant improvement of refill adherence when an ERD was
used with or without counseling. However, in a subgroup of
women using statins for secondary prevention the ERD-improved
adherence was statistically significant.
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APPENDIXES
APPENDIX 1: TRANSLATED INVITATION LETTER FOR COUNSELING
Dear Sir/Madam,
In the Netherlands more than one million patients use
cholesterol-lowering agents each year. As a user of . . . (simvas-
tatin) you are one of them. These drugs must be taken every
day. Research shows that many patients have difficulty adhering
to this.
I would like to invite you to visit the pharmacy and talk about
the use of . . . (simvastatin). Perhaps you have questions about this
medicine, you may have experienced side effects or you might be
uncertain about how to see it. We can discuss these things during
our talk. As a pharmacist, I also need to know about how these
drugs are used in practice and about any problems thatmight pre-
vent their proper use. I would like to hear about your experience
as a user.
Please could you be so kind as to contact the pharmacy tomake
an appointment. At the bottom of this letter you will find some
suggestions for suitable dates and times. If none of these are con-
venient for you then please contact the pharmacy to see if another
date and time is available.
Yours faithfully,
Your pharmacist
Original text in Dutch:
Geachte heer/mevrouw,
In Nederland gebruiken jaarlijks momenteel meer dan
één miljoen patiënten cholesterolverlagende middelen. U als
gebruiker van . . . (simvastatine) bent hier één van. Deze
geneesmiddelen moeten iedere dag ingenomen worden. Uit
onderzoek blijkt dat veel patiënten hier moeite mee hebben.
Graag zou ik u willen uitnodigen om langs te komen in de
apotheek en te praten over het gebruik van . . . (simvastatine).
Wellicht heeft u vragen over dit geneesmiddel, heeft u bijvoor-
beeld last van bijwerkingen of twijfelt u aan de werking of het nut.
Tijdens dit gesprek kunt u dit allemaal ter sprake brengen. Voor
mij als apotheker is het ook belangrijk om te weten hoe dit soort
geneesmiddelen in de praktijk gebruikt worden en of er proble-
men zijn die goed gebruik in de weg staan. Dat wil ik graag van u
als gebruiker horen.
Onderaan deze brief vindt u een aantal tijdstippen waarvoor
u een afspraak kunt maken door met uw apotheek te bellen.
Mogelijk zit er geen tijdstip bij waarop u kunt. Na overleg met
u kan er dan een ander tijdstip afgesproken worden.
Met vriendelijke groet,
Uw apotheker
APPENDIX 2: TRANSLATED INFORMATION LETTER FOR ERD-ONLY
GROUP
Dear Sir/Madam,
In the Netherlands more than one million patients use
cholesterol-lowering agents each year. As a user of . . . (simvas-
tatin) you are one of them. These drugs must be taken every
day. Research shows that many patients have difficulty adhering
to this.
To help you with your daily intake we are sending you a device.
This device is designed specifically for people who need to take
medicines every day. It gives a signal at a specific time. The next
time you have to take . . . (simvastatin) just activate the device by
pressing and holding this button, youwill hear a beep. Afterwards,
this device will warn you every day at the same time so that you
remember to take . . . (simvastatin). You can then turn off the
device by pressing the button. I hope this device helps you to
take . . . (simvastatin) daily. You will not be charged for this advice.
If you have any questions about this letter then please do not
hesitate to phone or to pop in to the pharmacy.
Yours faithfully,
Your pharmacist
Original text in Dutch:
Geachte heer/mevrouw,
In Nederland gebruiken jaarlijks momenteel meer dan
één miljoen patiënten cholesterolverlagende middelen. U als
gebruiker van . . . (simvastatine) bent hier één van. Deze
geneesmiddelen moeten iedere dag ingenomen worden. Uit
onderzoek blijkt dat veel patiënten hier moeite mee hebben.
Om u te helpen met de dagelijkse inname ontvangt u een
apparaatje. Dit apparaatje is speciaal ontwikkeld voor mensen
die dagelijks medicijnen moeten innemen. Dit apparaatje geeft
op een door u ingesteld tijdstip een signaal af. De eerstvolgende
keer dat u . . . (simvastatine) inneemt activeert u het apparaatje
door de knop ingedrukt te houden, u hoort dan een piepsig-
naal. Vervolgens zal dit apparaatje u elke dag op hetzelfde tijdstip
waarschuwen. Op deze manier wordt u er iedere dag aan herin-
nerd wanneer het tijd is . . . (simvastatine) weer in te nemen. U
kunt het apparaatje dan uitzetten door nogmaals op de knop te
drukken. Ik hoop dat dit apparaatje u helpt om . . . (simvasta-
tine) dagelijks in te nemen. Er zijn voor u overigens geen kosten
verbonden aan dit apparaatje.
Als u nog vragen heeft naar aanleiding van deze brief, dan kunt
u natuurlijk altijd even bellen of langskomen.
Met vriendelijke groet,
Uw apotheker
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